News | May 31, 2021
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
7.5 crore antenatal check-ups and 1.2 crore high-risk pregnancies identified under flagship programme as maternal and neonatal mortality declines
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
Bengaluru-based startup will use the fresh capital to enter new markets, enhance technology capabilities, and scale its integrated care model
Subscribe To Our Newsletter & Stay Updated
